Trial Profile
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK (Bruton Tyrosine Kinase) or PI3K-Delta (Phosphoinositide-3-kinase) Inhibitor Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Umbralisib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors TG Therapeutics Inc
- 19 Jul 2021 Status changed from active, no longer recruiting to completed.
- 05 May 2021 Planned End Date changed from 1 Jun 2021 to 1 Jul 2021.
- 05 May 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Jul 2021.